Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

Preclinical and clinical development of a YFV 17 D-based chimeric vaccine against West Nile virus.

Dayan GH, Pugachev K, Bevilacqua J, Lang J, Monath TP.

Viruses. 2013 Dec 9;5(12):3048-70. doi: 10.3390/v5123048. Review.

2.

Phase II, dose ranging study of the safety and immunogenicity of single dose West Nile vaccine in healthy adults ≥ 50 years of age.

Dayan GH, Bevilacqua J, Coleman D, Buldo A, Risi G.

Vaccine. 2012 Oct 19;30(47):6656-64. doi: 10.1016/j.vaccine.2012.08.063. Epub 2012 Sep 7.

PMID:
22959989
3.

Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults.

Biedenbender R, Bevilacqua J, Gregg AM, Watson M, Dayan G.

J Infect Dis. 2011 Jan 1;203(1):75-84. doi: 10.1093/infdis/jiq003.

Supplemental Content

Loading ...
Support Center